Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
16.96
+2.33 (15.93%)
At close: Nov 4, 2024, 4:00 PM
16.90
-0.06 (-0.35%)
After-hours: Nov 4, 2024, 5:53 PM EST
Monopar Therapeutics Employees
As of December 31, 2023, Monopar Therapeutics had 10 total employees, including 9 full-time and 1 part-time employees. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-$712,418
Market Cap
87.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi | 236 |
| Xtant Medical Holdings | 215 |
| Rani Therapeutics Holdings | 140 |
| RAPT Therapeutics | 131 |
| Adlai Nortye | 127 |
| ALX Oncology Holdings | 72 |
| electroCore | 68 |
| Clearside Biomedical | 30 |
MNPR News
- 5 days ago - Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock? - Forbes
- 11 days ago - Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder - Benzinga
- 13 days ago - Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 - GlobeNewsWire
- 20 days ago - Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers - GlobeNewsWire
- 7 weeks ago - Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr - GlobeNewsWire